Margarita Fernández

Margarita Fernández

Auto-generated profile, based on publicly available information

Margarita Fernández

Dep. Bioquímica y Biología Molecular II, Facultad de Farmacia, Universidad Complutense, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
ASAmileth Suarez-Causado
Amileth Suarez-Causado
DCDaniel Caballero-Diaz
Daniel Caballero-Diaz
EBEsther Bertran
Esther Bertran
CRC. Roncero
C. Roncero
AAA. Addante
A. Addante
Aránzazu SánchezAránzazu Sánchez
Aránzazu Sánchez

Verified
Journal Article
Open access
PDF file
MÁMaría García Álvaro
María García Álvaro
AAAnnalisa Addante
Annalisa Addante
CRCesáreo Roncero
Cesáreo Roncero
MFMargarita Fernández
Margarita Fernández
Isabel FabregatIsabel Fabregat
Isabel Fabregat
Blanca HerreraBlanca Herrera
Blanca Herrera
The study of bone morphogenetic proteins (BMPs) role in tumorigenic processes, and specifically in the liver, has gathered importance in the last few years. Previous studies have shown that BMP9 is overexpressed in about 40% of hepatocellular carcinoma (HCC) patients. In vitro data have also shown evidence that BMP9 has a pro-tumorigenic action, not only by inducing epithelial to mesenchymal transition (EMT) and migration, but also by promoting proliferation and survival in liver cancer cells. However, the precise mechanisms driving these effects have not yet been established. In the present work, we deepened our studies into the intracellular mechanisms implicated in the BMP9 proliferative and pro-survival effect on liver tumor cells. In HepG2 cells, BMP9 induces both Smad and non-Smad signaling cascades, specifically PI3K/AKT and p38MAPK. However, only the p38MAPK pathway contributes to the BMP9 growth-promoting effect on these cells. Using genetic and pharmacological approaches, we demonstrate that p38MAPK activation, although dispensable for the BMP9 proliferative activity, is required for the BMP9 protective effect on serum withdrawal-induced apoptosis. These findings contribute to a better understanding of the signaling pathways involved in the BMP9 pro-tumorigenic role in liver tumor cells.